NewAmsterdam Pharma PREVAIL Trial Options Activity Noted

By EC Assets · Published 8 September 2026

NewAmsterdam Pharma's options activity indicates institutional positioning related to its PREVAIL trial. The company has scheduled the PREVAIL interim analysis for the fourth quarter of 2026. This analysis follows encouraging blinded trends observed in the trial. NewAmsterdam Pharma Company N.V. is a late-stage, clinical biopharmaceutical firm. It is traded on Nasdaq under the ticker NAMS. The company previously outlined its 2026 strategic priorities in January. NewAmsterdam Pharma also announced three presentations at the 2026 American College of Cardiology Annual Scientific Session in March. The company's stock has experienced a significant pullback. This occurred after Merck received approval for Lipfendra. NewAmsterdam Pharma has a current rating of Hold. The company has discussed its clinical development update and plans for the PREVAIL trial's interim analysis. NewAmsterdam Pharma focuses on lowering Lp(a) to reduce the risk of cardiovascular events. The PREVAIL trial interim analysis in Q4 2026 represents a key upcoming event for NewAmsterdam Pharma. This article is intended for informational purposes only. It does not constitute investment advice.